KalVista Pharmaceuticals, Inc.
KALV
$14.66
$1.148.43%
NASDAQ
| 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -60.10M | -52.23M | -48.51M | -- |
| Total Depreciation and Amortization | -- | 252.00K | 261.00K | 229.00K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 10.04M | 62.00K | 10.01M | -- |
| Change in Net Operating Assets | -- | -4.70M | 11.54M | 5.59M | -- |
| Cash from Operations | -- | -54.50M | -40.36M | -32.68M | -39.64M |
| Capital Expenditure | -- | -290.00K | -281.00K | -24.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 21.55M | -3.05M | 8.54M | -- |
| Cash from Investing | -- | 21.26M | -3.33M | 8.52M | 48.67M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 1.29M | 1.85M | 56.54M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 21.92M | 2.81M | 95.23M | -- |
| Cash from Financing | -- | 23.21M | 4.66M | 151.77M | 295.00K |
| Foreign Exchange rate Adjustments | -- | 2.72M | 3.36M | -1.25M | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -7.31M | -35.67M | 126.36M | 9.73M |